Inhibition of IL-6 family cytokines by SOCS3

Seminars in Immunology

Volumn 26, Issue 1, 2014, Pages 13-19

  Babon, Jeffrey J ^a,b   Varghese, Leila N ^a,b   Nicola, Nicos A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokine signalling; IL 6; JAK STAT; Janus Kinases; SOCS

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE TYK2; SUPPRESSOR OF CYTOKINE SIGNALING 3;

CATALYSIS; ENZYME ACTIVITY; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW;

CYTOKINE SIGNALLING; IL-6; JAK/STAT; JANUS KINASES; SOCS;

ANIMALS; CATALYSIS; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; JANUS KINASES; MODELS, BIOLOGICAL; MULTIGENE FAMILY; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84896489589     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.12.004     Document Type: Review

References (86)

1. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888.
2. Guidebook to cytokines and their receptors 1994, Oxford University Press, Oxford. N.A. Nicola (Ed.).
3. Wang X., Lupardus P., Laporte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009, 27:29-60.
4. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
5. Xu Y., Kershaw N.J., Luo C.S., Soo P., Pocock M.J., Czabotar P.E., et al. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem 2010, 285:21214-21218.
6. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
7. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994, 300(Pt 2):281-290.
8. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
9. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997, 17:2497-2501.
10. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
11. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997, 16:5572-5581.
12. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92-95.
13. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
14. Hemmann U., Gerhartz C., Heesel B., Sasse J., Kurapkat G., Grotzinger J., et al. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem 1996, 271:12999-13007.
15. Eulenfeld R., Dittrich A., Khouri C., Muller P.J., Mutze B., Wolf A., et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 2012, 91:486-495.
16. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
17. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
18. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
19. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N.A., Gilbert D.J., Copeland N.G., et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995, 14:2816-2826.
20. Masuhara M., Sakamoto H., Matsumoto A., Suzuki R., Yasukawa H., Mitsui K., et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 1997, 239:439-446.
21. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997, 89:3148-3154.
22. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 1998, 95:114-119.
23. Liongue C., O'Sullivan L.A., Trengove M.C., Ward A.C. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS ONE 2012, 7:e32777.
24. Liongue C., Ward A.C. Evolution of the JAK-STAT pathway. JAKSTAT 2013, 2:e22756.
25. Linossi E.M., Chandrashekaran I.R., Kolesnik T.B., Murphy J.M., Webb A.I., Willson T.A., et al. Suppressor of cytokine signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS ONE 2013, 8:e70536.
26. Nicholson S.E., Metcalf D., Sprigg N.S., Columbus R., Walker F., Silva A., et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci U S A 2005, 102:2328-2333.
27. Stec W.J., Zeidler M.P. Drosophila SOCS proteins. J Signal Transduct 2011, 2011:894510.
28. Callus B.A., Mathey-Prevot B. SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc. Oncogene 2002, 21:4812-4821.
29. Zheng N., Schulman B.A., Song L., Miller J.J., Jeffrey P.D., Wang P., et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416:703-709.
30. Mahrour N., Redwine W.B., Florens L., Swanson S.K., Martin-Brown S., Bradford W.D., et al. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J Biol Chem 2008, 283:8005-8013.
31. Muniz J.R., Guo K., Kershaw N.J., Ayinampudi V., von Delft F., Babon J.J., et al. Molecular architecture of the ankyrin SOCS box family of Cul5-dependent E3 ubiquitin ligases. J Mol Biol 2013, 425:3166-3177.
32. Bullock A.N., Debreczeni J.E., Edwards A.M., Sundstrom M., Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A 2006, 103:7637-7642.
33. Bullock A.N., Rodriguez M.C., Debreczeni J.E., Songyang Z., Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 2007, 15:1493-1504.
34. Babon J.J., Sabo J.K., Soetopo A., Yao S.G., Bailey M.F., Zhang J.G., et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol 2008, 381:928-940.
35. Boyle K., Egan P., Rakar S., Willson T.A., Wicks I.P., Metcalf D., et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 2007, 110:1466-1474.
36. Boyle K., Zhang J.G., Nicholson S.E., Trounson E., Babon J.J., McManus E.J., et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal 2009, 21:394-404.
37. Greenhalgh C.J., Metcalf D., Thaus A.L., Corbin J.E., Uren R., Morgan P.O., et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002, 277:40181-40184.
38. Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 2005, 115:2462-2471.
39. Pazienza V., Clement S., Pugnale P., Conzelman S., Foti M., Mangia A., et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
40. Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 2005, 280:7038-7048.
41. Verdier F., Chretien S., Muller O., Varlet P., Yoshimura A., Gisselbrecht S., et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem 1998, 273:28185-28190.
42. Ram P.A., Waxman D.J. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 2000, 275:39487-39496.
43. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
44. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4:551-556.
45. Croker B.A., Kiu H., Pellegrini M., Toe J., Preston S., Metcalf D., et al. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol 2012, 90:124-129.
46. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003, 4:540-545.
47. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004, 20:153-165.
48. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 2001, 98:9324-9329.
49. Mori H., Hanada R., Hanada T., Aki D., Mashima R., Nishinakamura H., et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004, 10:739-743.
50. Kievit P., Howard J.K., Badman M.K., Balthasar N., Coppari R., Mori H., et al. Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 2006, 4:123-132.
51. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4:546-550.
52. Croker B.A., Mielke L.A., Wormald S., Metcalf D., Kiu H., Alexander W.S., et al. Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. Exp Hematol 2008, 36:786-798.
53. Wormald S., Zhang J.G., Krebs D.L., Mielke L.A., Silver J., Alexander W.S., et al. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 2006, 281:11135-11143.
54. Auernhammer C.J., Bousquet C., Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A 1999, 96:6964-6969.
55. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially cytokine signaling 3. J Immunol 2003, 170:3263-3272.
56. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 2000, 97:6493-6498.
57. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000, 275:12848-12856.
58. De Souza D., Fabri L.J., Nash A., Hilton D.J., Nicola N.A., Baca M. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 2002, 41:9229-9236.
59. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003, 278:661-671.
60. Babon J.J., Yao S., DeSouza D.P., Harrison C.F., Fabri L.J., Liepinsh E., et al. Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J 2005, 272:6120-6130.
61. Bergamin E., Wu J., Hubbard S.R. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 2006, 14:1285-1292.
62. Pawson T., Gish G.D. SH2 and SH3 domains: from structure to function. Cell 1992, 71:359-362.
63. Koch C.A., Moran M., Sadowski I., Pawson T. The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function. Mol Cell Biol 1989, 9:4131-4140.
64. DeClue J.E., Sadowski I., Martin G.S., Pawson T. A conserved domain regulates interactions of the v-fps protein-tyrosine kinase with the host cell. Proc Natl Acad Sci U S A 1987, 84:9064-9068.
65. Grucza R.A., Bradshaw J.M., Futterer K., Waksman G. SH2 domains: from structure to energetics, a dual approach to the study of structure-function relationships. Med Res Rev 1999, 19:273-293.
66. Ladbury J.E., Lemmon M.A., Zhou M., Green J., Botfield M.C., Schlessinger J. Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. Proc Natl Acad Sci U S A 1995, 92:3199-3203.
67. Fairlie W.D., De Souza D., Nicola N.A., Baca M. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2. Biochem J 2003, 372:495-502.
68. Hortner M., Nielsch U., Mayr L.M., Johnston J.A., Heinrich P.C., Haan S. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol 2002, 169:1219-1227.
69. Hortner M., Nielsch U., Mayr L.M., Heinrich P.C., Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem 2002, 269:2516-2526.
70. Rogers S., Wells R., Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986, 234:364-368.
71. Babon J.J., McManus E.J., Yao S., DeSouza D.P., Mielke L.A., Sprigg N.S., et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol Cell 2006, 22:205-216.
72. Sasaki A., Inagaki-Ohara K., Yoshida T., Yamanaka A., Sasaki M., Yasukawa H., et al. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J Biol Chem 2003, 278:2432-2436.
73. Haan S., Ferguson P., Sommer U., Hiremath M., McVicar D.W., Heinrich P.C., et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem 2003, 278:31972-31979.
74. Chen X.P., Losman J.A., Cowan S., Donahue E., Fay S., Vuong B.Q., et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 2002, 99:2175-2180.
75. Forrai A., Boyle K., Hart A.H., Hartley L., Rakar S., Willson T.A., et al. Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells 2006, 24:604-614.
76. Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996, 5:449-460.
77. Narazaki M., Fujimoto M., Matsumoto T., Morita Y., Saito H., Kajita T., et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A 1998, 95:13130-13134.
78. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999, 4:339-351.
79. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999, 18:1309-1320.
80. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000, 275:29338-29347.
81. Kershaw N.J., Murphy J.M., Liau N.P., Varghese L.N., Laktyushin A., Whitlock E.L., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013, 20:469-476.
82. Babon J.J., Kershaw N.J., Murphy J.M., Varghese L.N., Laktyushin A., Young S.N., et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 2012, 36:239-250.
83. Song M.M., Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 1998, 273:35056-35062.
84. Ram P.A., Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999, 274:35553-35561.
85. Cohney S.J., Sanden D., Cacalano N.A., Yoshimura A., Mui A., Migone T.S., et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999, 19:4980-4988.
86. Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell 2005, 20:325-333.